Akèy › Kansè Poumon ki pa ti selil › Distrik Columbia › Washington
Etid klinik pou Kansè Poumon ki pa ti selil nan Washington, DC
55 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Washington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- ak 1 plis
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Local Institution - 0183, Washington D.C.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Ap rekriteFaz 3
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Washington D.C.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Ap rekriteEtid obsèvasyon
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi lwen
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi lwen
- Maryland Oncology Hematology, P.A, Largo · 11 mi lwen
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Silver Spring · 7 mi lwen
- Research Site, Bethesda · 7 mi lwen
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi lwen
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi lwen
- Maryland Oncology Hematology, P.A., Largo · 11 mi lwen
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
- Washington DC VA Medical Center, Washington D.C.
- Maryland Oncology Hematology P A, Silver Spring · 7 mi lwen
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Georgetown University, Washington D.C.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ap rekriteFaz 3
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Sibley Memorial Hospital, Washington D.C.
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Ap rekriteFaz 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Bethesda · 7 mi lwen
- Research Site, Bethesda · 7 mi lwen
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- George Washington University Cancer Center, Washington D.C.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-5476, Washington D.C.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Sibley Memorial Hospital, Washington D.C.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Walter Reed National Military Medical Center, Bethesda · 7 mi lwen
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- Washington Hospital Center ( Site 0037), Washington D.C.
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi lwen
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Bethesda · 7 mi lwen
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- MedStar Georgetown University Hospital, Washington D.C.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sibley Memorial Hospital, Washington D.C.
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- National Institutes of Health, Bethesda · 7 mi lwen
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Georgetown University Medical Center, Washington D.C.
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Ap rekriteFaz 2
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Georgetown University, Washington D.C.
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Maryland Oncology Hematology, Calverton · 12 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Georgetown University Medical Center, Washington D.C.
Gilteritinib for the Treatment of ALK NSCLC
Ap rekriteFaz 1
- Georgetown University, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Georgetown University Medical Center, Washington D.C.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi lwen
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA11-0, Bethesda · 7 mi lwen
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Ap rekriteFaz 3
- Georgetown University Medical Cener (GUMC), Washington D.C.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Washington D.C.
- Research Site, Bethesda · 7 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi lwen
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- Sibley Memorial Hospital, Washington D.C.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ap rekriteFaz 1
- National Cancer Institute, Bethesda · 7 mi lwen
Repositioning Immunotherapy in VetArans With Lung Cancer
Ap rekriteFaz 2
- VA Central Office, Washington, DC, Washington D.C.
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- The Center for Cancer and Blood Disorder, Bethesda · 7 mi lwen
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Ap rekriteFaz 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi lwen
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi lwen
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Ap rekriteFaz 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Seattle, WA53 etid
Lòt etid nan Washington
- Kansè (tout kalite)58 etid
- Kansè nan tete46 etid
- Kansè Metastatik43 etid
- Kansè poumon41 etid
- Kansè pwostat38 etid
- Obèsite33 etid
- Kansè kolorektal29 etid
- Maladi kadyovaskilè28 etid
- Kansè vejik26 etid
- Leksemi mieloïd egi24 etid
- Kansè ovè23 etid
- Limfom23 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.